Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis

Summary

We studied haemostasis in two mouse models with thrombocytosis caused by different pathogenic mechanisms. In one strain (Yall;Mpl-/-) thrombocytosis is driven by a misbalance between thrombopoietin and its receptor, whereas in the other strain, thrombocytosis is caused by expressing a human JAK2-V617F transgene (FF1) that depends on activation by Cre-recombinase (VavCre;FF1, MxCre;FF1). Thrombotic responses were increased following some, but not all types of challenges. In a vaso-occlusive thrombotic model following collagen-adrenaline injection we found increased mortality in both strains. Arterial thrombosis, examined after ferric chloride-induced carotid injury, was accelerated but with little impact on maximal thrombus size. In a vena cava stasis model, clots were of similar size as in wild-type controls, but exhibited a different composition with a higher platelet to fibrin ratio. Both thrombocytosis strains displayed increased haemorrhagic tendency in a tail bleeding assay. Yall;Mpl and VavCre;FF1 displayed a lower proportion of the more reactive high-molecular-weight forms of von Willebrand factor in their plasma, mimicking essential thrombocythaemia with very high platelet counts. Bleeding could not be explained by clear defects in platelet activation, which were normal or only weakly decreased. In conclusion, these models of thrombocytosis recapitulate several features of the haemorrhagic and thrombotic diatheses in ET and PV demonstrating potentials but also some limitations to study these major complications.

Keywords

Thrombocytosis - haemorrhages - thrombotic tendency

• References

• 1 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320.
• 2 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122: 2176-2184.
• 3 Li J, Spensberger D, Ahn JS. et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010; 116: 1528-1538.
• 4 Carobbio A, Finazzi G, Guerini V. et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310-2313.
• 5 Bellucci S, Michiels JJ. The role of JAK2 V617F mutation, spontaneous erythro-poiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythe-mia vera and essential thrombocythemia. Semin Thromb Haemost 2006; 32: 381-398.
• 6 Michiels JJ, Berneman Z, Schroyens W. et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006; 17: 528-544.
• 7 Campbell PJ, MacLean C, Beer PA. et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012; 120: 1409-1411.
• 8 Carobbio A, Finazzi G, Antonioli E. et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112: 3135-3137.
• 9 Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997; 23: 425-431.
• 10 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine ki-nase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
• 11 James C, Ugo V, Le Couedic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
• 12 Kralovics R, Passamonti F, Buser AS. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
• 13 Levine RL, Wadleigh M, Cools J. et al. Activating mutation in the tyrosine ki-nase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 07: 387-397.
• 14 Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-2466.
• 15 Xu W, Li JY, Xia J. et al. MPL W515L mutation in Chinese patients with myelo-proliferative diseases. Leuk Lymphoma 2008; 49: 955-958.
• 16 Lacout C, Pisani DF, Tulliez M. et al. JAK2V617F expression in murine hemato-poietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.
• 17 Wernig G, Mercher T, Okabe R. et al. Expression of Jak2V617F causes a poly-cythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-4281.
• 18 Zaleskas VM, Krause DS, Lazarides K. et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 01: e18.
• 19 Hobbs CM, Manning H, Bennett C. et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 2013; 122: 3787-3797.
• 20 Tiedt R, Coers J, Ziegler S. et al. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 2009; 113: 1768-1777.
• 21 Tiedt R, Hao-Shen H, Sobas MA. et al. Ratio of mutant JAK2-V617F to wildtype Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
• 22 Kuhn R, Schwenk F, Aguet M. et al. Inducible gene targeting in mice. Science 1995; 269: 1427-1429.
• 23 de Boer J, Williams A, Skavdis G. et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol 2003; 33: 314-325.
• 24 Kubovcakova L, Lundberg P, Grisouard J. et al. Differential effects of hydroxyu-rea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood 2013; 121: 1188-1199.
• 25 Eckly A, Hechler B, Freund M. et al. Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost 09: 779-789..
• 26 Brill A, Fuchs TA, Chauhan AK. et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117: 1400-1407.
• 27 Hechler B, Gachet C. Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. Thromb Haemost 2011; 105 (Suppl. 01) S3-12.
• 28 Cazenave JP, Ohlmann P, Cassel D. et al. Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 2004; 272: 13-28.
• 29 Legendre P, Navarrete AM, Rayes J. et al. Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood 2013; 121: 2135-2143.
• 30 Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 2012; 26: 563-571.
• 31 Bellucci S, Michiels JJ. Spontaneous proliferative megakaryocytopoiesis and platelet hyperreactivity in essential thrombocythemia: is thrombopoietin the link?. Ann Hematol 2000; 79: 51-58.
• 32 Lanza F, Beretz A, Stierle A. et al. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-1288.
• 33 Lamrani L, Lacout C, Ollivier V. et al. Haemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood 2014; 124: 1136-1145.
• 34 Etheridge SL, Roh ME, Cosgrove ME. et al. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014; 111: 2295-2300.
• 35 Budde U, Dent JA, Berkowitz SD. et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68: 1213-1217.
• 36 Fabris F, Casonato A, Grazia del Ben M. et al. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986; 63: 75-83.
• 37 Mohri H. Acquired von Willebrand disease in patients with polycythemia rubra vera. Am J Hematol 1987; 26: 135-146.
• 38 Finazzi G, Budde U, Michiels JJ. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leuk Lymphoma 1996; 22 (Suppl. 01) 71-78.
• 39 Grignani C, Noris P, Tinelli C. et al. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?. Platelets 2009; 20: 131-134.
• 40 Renne T, Pozgajova M, Gruner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
• 41 Falanga A, Marchetti M, Evangelista V. et al. Polymorphonuclear leukocyte activation and haemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-4266.
• 42 von Bruhl ML, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.